Evicenter
Rinvoq (upadacitinib) in Rheumatoid arthritis
Manufacturer
AbbVie Inc.
Prescribing information
Rinvoq (opens in a new tab)
Questions
42
Last updated

All questions

Clinical trials: Rinvoq (upadacitinib) in rheumatoid arthritis

5 questions · 2 sources

SELECT-SWITCH

How was the RINVOQ vs HUMIRA SELECT-SWITCH trial designed?

RINVOQ vs HUMIRA (adalimumab) in SELECT-SWITCH: what did the Week 12 comparison show?

Note: The page states superiority at Week 12 and shows the remission and low disease activity percentages only in charts, so no rates, differences, or p-values are quoted here. The Week 48 comparison was not controlled for multiplicity.

RINVOQ vs HUMIRA: what side effects were reported through Week 48 (SELECT-SWITCH)?

Note: Each table row lists the HUMIRA result first and the RINVOQ result second.

SELECT-BEYOND

Does RINVOQ work for rheumatoid arthritis after biologic DMARDs failed or were not tolerated (SELECT-BEYOND)?

Note: This efficacy page describes SELECT-BEYOND as a 24-week study; the rheumatoid arthritis overview page (rinvoqhcp.com/rheumatoid-arthritis) describes it as a 12-week study.

What share of RINVOQ patients were in remission at 5 years (SELECT-BEYOND)?